Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

Experts discuss what partnerships between academic and community settings look like with regard to bispecifics, highlighting the role academic centers play in supporting community practices with bispecific therapy protocols.

EP: 1.Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP: 2.Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

EP: 3.How Bispecific Antibodies Are Reshaping Cancer Care

EP: 4.Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

EP: 5.Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

EP: 6.Overcoming Key Operational Challenges in Integrating Bispecific Therapies

Now Viewing

EP: 7.Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

EP: 8.Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

EP: 9.Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy

EP: 10.Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

EP: 11.Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

EP: 12.Payer and Reimbursement Considerations for Bispecific Therapies

EP: 13.Emerging Therapeutic Areas for Bispecific Antibodies

EP: 14.Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

EP: 15.Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Video content above is prompted by the following:

What do partnerships look like between academic and community settings with regard to bispecifics?

What role do academic centers play in supporting community practices with bispecific therapy protocols?

Related Videos

Related Content

Advertisement

April 23rd 2025

Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis

Brooke McCormick

Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

April 17th 2025

Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays

Brooke McCormick

Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.

Related Content

Advertisement

April 23rd 2025

Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis

Brooke McCormick

Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

April 17th 2025

Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays

Brooke McCormick

Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.